The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine‐based therapy. This study aims to expl...

Full description

Bibliographic Details
Main Authors: Letizia Procaccio, Valeria Merz, Morena Fasano, Vanja Vaccaro, Elisa Giommoni, Andrea Pretta, Silvia Noventa, Maria Antonietta Satolli, Guido Giordano, Clizia Zichi, Carmine Pinto, Camilla Zecchetto, Giulia Barsotti, Ferdinando De Vita, Michele Milella, Lorenzo Antonuzzo, Mario Scartozzi, Alberto Zaniboni, Rosella Spadi, Simona Casalino, Francesca Bergamo, Chiara De Toni, Davide Melisi, Sara Lonardi
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.6111

Internet

https://doi.org/10.1002/cam4.6111

Similar Items